Pathology
Cancer research at Wood Hudson has progressed since research began here in 1981. Technological advancements have enabled the laboratories at Wood Hudson to share research discoveries, decode complex information, and disseminate information to the scientific community in astonishing ways. There are many scientific instruments that make these advancements possible, but perhaps some of the most useful instruments are the:
- Nikon 2X Coolscope Digital Microscope
- Nikon DS Fi-1 Camera
In 2007, these instruments were funded with the generous support of The Lexington Cancer Foundation, which has a stated goal of "raising funds and awareness in the fight against cancer." The Lexington Cancer Foundation uses donations to fund various causes in Kentucky that promote cancer awareness, provide support for people with cancer, further cancer research, and create better lives for people living with cancer. Wood Hudson Cancer Research Laboratory is grateful to foundations such as The Lexington Cancer Foundation that support our cancer research mission and thereby enhance our research capabilities and enable research discoveries.
Cancer research at Wood Hudson has progressed since research began here in 1981. Technological advancements have enabled the laboratories at Wood Hudson to share research discoveries, decode complex information, and disseminate information to the scientific community in astonishing ways. There are many scientific instruments that make these advancements possible, but perhaps some of the most useful instruments are the:
- Nikon 2X Coolscope Digital Microscope
- Nikon DS Fi-1 Camera
In 2007, these instruments were funded with the generous support of The Lexington Cancer Foundation, which has a stated goal of "raising funds and awareness in the fight against cancer." The Lexington Cancer Foundation uses donations to fund various causes in Kentucky that promote cancer awareness, provide support for people with cancer, further cancer research, and create better lives for people living with cancer. Wood Hudson Cancer Research Laboratory is grateful to foundations such as The Lexington Cancer Foundation that support our cancer research mission and thereby enhance our research capabilities and enable research discoveries.
Molecular Biology
Wood Hudson's Molecular Biologist is Dr. Stefan Siwko. Molecular biology is the study of biology at the molecular level with the goal of understanding the interactions between different systems operating within a cell. At Wood Hudson our Molecular Biology program focuses on deciphering the cellular function of proteins that cause cancer. Dr. Siwko has mentored approximately thirteen students in the Undergraduate Research Education Program.
Wood Hudson's Molecular Biologist is Dr. Stefan Siwko. Molecular biology is the study of biology at the molecular level with the goal of understanding the interactions between different systems operating within a cell. At Wood Hudson our Molecular Biology program focuses on deciphering the cellular function of proteins that cause cancer. Dr. Siwko has mentored approximately thirteen students in the Undergraduate Research Education Program.
WHCRL 1981-2011
Website Design by Jared Queen
The goal of the Molecular Biology Laboratory at Wood Hudson Cancer Research
Laboratory is to further the findings of the Pathobiology Laboratory through unraveling
the biological functions of proteins that are altered in human cancers. Cancer is a
complicated process that affects many proteins in a cell. Identifying which proteins are
altered in tumors as compared with normal tissue is an important step, but not all of
these changed proteins are vital for tumor development and spread.
In the Molecular Biology Laboratory, we study proteins by increasing or decreasing their expression in cancer cells grown under controlled conditions, and look for changes in cell growth, resistance to drugs, invasiveness, and other biological processes important in tumor progression. In this way, we better understand the significance of the proteins determined to be altered in human cancers, and can home in on those proteins that are most promising as targets for therapeutic development.
In the Molecular Biology Laboratory, we study proteins by increasing or decreasing their expression in cancer cells grown under controlled conditions, and look for changes in cell growth, resistance to drugs, invasiveness, and other biological processes important in tumor progression. In this way, we better understand the significance of the proteins determined to be altered in human cancers, and can home in on those proteins that are most promising as targets for therapeutic development.
931 Isabella St. Newport, KY 41071
Phone (859) 581-7249 ~ Fax (859) 581-2392
Phone (859) 581-7249 ~ Fax (859) 581-2392
Working towards the conquest of cancer through research since 1981.
Cancer Research is Progressing.
Wood Hudson Cancer Research Laboratory scientists presented three research reports at the American Association for Cancer Research 102nd Annual Meeting. The annual conference of trained healthcare professionals took place in Orlando, Florida from April 2-6, 2011. Thousands of cancer research experts presented findings at the annual meeting and Wood Hudson was pleased to present research on prostate cancer, ovarian cancer, and potential cancer treatments.
Wood Hudson has now published or presented 172 research reports. Visit the American Association for Cancer Research, or AACR, to learn more about Wood Hudson’s research.
The following are the reports presented by Wood Hudson scientists at the AACR Annual Meeting:
“Overexpression of Cathepsin L is Associated with Prostate Cancer Development, Progression, and Reduced Patient Survival.” Authors: Julia H. Carter, Larry E. Douglass, James A. Deddens, Bruce M. Colligan, Bernadette M. Hurst, Janice Pullman, Raymond E. Richmond, and Harry W. Carter. Wood Hudson Cancer Research Laboratory, Newport, KY; University of Cincinnati, Cincinnati, OH.
“The Germ-line Variant Int7G24A of the TGFBR1 Gene Identifies Women at Risk for Development and Death from Serious and Endometrioid Ovarian Cancer.” Authors: Julia H. Carter, James P. Schaeper, James A. Deddens, Taiping Chen, Bruce M. Colligan, Jessica L. DeBrosse, Robert J. Shields, Kevin Murray, Briana Vogt, Michael P. Markey, Chad R. Jackson, Kathy S. Wang, Denise Lucas, Jackson O. Pemberton, Larry E. Douglass, and Jeremy R. Graff. Wood Hudson Cancer Research Laboratory, Newport KY; University of Cincinnati, Cincinnati, OH; St. Elizabeth Healthcare, Edgewood, KY; Eli Lilly and Company, Indianapolis, IN.
“Elevated eIF4E Phosphorylation is Associated with Advanced Malignancy and Decreased Patient Survival and can be Therapeutically Inhibited by a Novel, Orally Bio-available Mnk Inhibitor.” Authors: Jeremy R. Graff, Bruce W. Konicek, Chad A. Dumstorf, Stefan Siwko, Bruce Colligan, James A. Deddens, Larry E. Douglass, and Julia H. Carter.
Wood Hudson Cancer Research Laboratory scientists presented three research reports at the American Association for Cancer Research 102nd Annual Meeting. The annual conference of trained healthcare professionals took place in Orlando, Florida from April 2-6, 2011. Thousands of cancer research experts presented findings at the annual meeting and Wood Hudson was pleased to present research on prostate cancer, ovarian cancer, and potential cancer treatments.
Wood Hudson has now published or presented 172 research reports. Visit the American Association for Cancer Research, or AACR, to learn more about Wood Hudson’s research.
The following are the reports presented by Wood Hudson scientists at the AACR Annual Meeting:
“Overexpression of Cathepsin L is Associated with Prostate Cancer Development, Progression, and Reduced Patient Survival.” Authors: Julia H. Carter, Larry E. Douglass, James A. Deddens, Bruce M. Colligan, Bernadette M. Hurst, Janice Pullman, Raymond E. Richmond, and Harry W. Carter. Wood Hudson Cancer Research Laboratory, Newport, KY; University of Cincinnati, Cincinnati, OH.
“The Germ-line Variant Int7G24A of the TGFBR1 Gene Identifies Women at Risk for Development and Death from Serious and Endometrioid Ovarian Cancer.” Authors: Julia H. Carter, James P. Schaeper, James A. Deddens, Taiping Chen, Bruce M. Colligan, Jessica L. DeBrosse, Robert J. Shields, Kevin Murray, Briana Vogt, Michael P. Markey, Chad R. Jackson, Kathy S. Wang, Denise Lucas, Jackson O. Pemberton, Larry E. Douglass, and Jeremy R. Graff. Wood Hudson Cancer Research Laboratory, Newport KY; University of Cincinnati, Cincinnati, OH; St. Elizabeth Healthcare, Edgewood, KY; Eli Lilly and Company, Indianapolis, IN.
“Elevated eIF4E Phosphorylation is Associated with Advanced Malignancy and Decreased Patient Survival and can be Therapeutically Inhibited by a Novel, Orally Bio-available Mnk Inhibitor.” Authors: Jeremy R. Graff, Bruce W. Konicek, Chad A. Dumstorf, Stefan Siwko, Bruce Colligan, James A. Deddens, Larry E. Douglass, and Julia H. Carter.
Three Research Papers Accepted for Presentation at AACR